Literature DB >> 8975769

Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.

E A Lock1, P Gaskin, M K Ellis, W M Provan, M Robinson, L L Smith, M P Prisbylla, L C Mutter.   

Abstract

Administration of a single oral dose of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione (NTBC) to rats produced a marked tyrosinemia in the plasma and aqueous humor. The tyrosinemia was both time- and dose-dependent with the duration being more marked at the higher doses. The dose-response curve was very steep with a single dose of 1.5 micromol NTBC/kg (0.5 mg/kg) and above producing maximal concentrations of tyrosine in plasma of about 2500 nmol/ml and in aqueous humor of about 3500-4000 nmol/ml at 24 hr after dosing. Analysis of the key hepatic enzymes involved in tyrosine catabolism showed that 4-hydroxyphenylpyruvate dioxygenase (HPPD) was markedly inhibited soon after dosing at either 0.3 or 30 micromol/kg (0.1 or 10 mg/kg) NTBC and that the activity recovered very slowly. In response to the tyrosinemia, the activity of tyrosine aminotransferase (TAT) in the liver was induced about twofold, while the activity of homogentisic acid oxidase (HGO) was not affected. Daily oral administration of NTBC for 6 weeks induced lesions to the cornea of the eye, with a dose of 0.3 micromol/kg/day producing about a 38% incidence and a higher dose of 30 micromol/kg/day a 75% incidence. Administration of a single oral dose of [14C]NTBC at either 0.3 or 30 micromol/kg led to selective retention of radiolabel in the liver and to a lesser extent in the kidneys and the Harderian gland. Concentrations of radioactivity in the liver and kidneys remained constant over 4 days and after the lower NTBC dose were about 2 nmol/g wet wt and 0.9 nmol/g wet wt, respectively. Subcellular fractionation of the liver showed that the majority of the radiolabel, >90%, was associated reversibly with the cytosol fraction. No retention of radiolabel was detected in the cornea, the site of toxicity. Our studies indicate that NTBC binds to protein in rat liver cytosol, inhibits the hepatic cytosolic enzyme HPPD, and causes a marked and sustained tyrosinemia. We suggest that this marked and sustained ocular tyrosinemia produced by NTBC in the rat is responsible for the corneal lesions since similar corneal lesions are produced by feeding rats a high tyrosine diet.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8975769     DOI: 10.1006/taap.1996.0310

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  12 in total

1.  Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.

Authors:  Megan A Hillgartner; Sarah B Coker; Ashton E Koenig; Marissa E Moore; Elizabeth Barnby; Gordon G MacGregor
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

Review 2.  The role of nitisinone in tyrosine pathway disorders.

Authors:  Edward Lock; Lakshminarayan R Ranganath; Oliver Timmis
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

3.  Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.

Authors:  M Khedr; S Judd; M C Briggs; A T Hughes; A M Milan; R M K Stewart; E A Lock; J A Gallagher; L R Ranganath
Journal:  JIMD Rep       Date:  2017-09-24

4.  Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.

Authors:  Ighovie F Onojafe; David R Adams; Dimitre R Simeonov; Jun Zhang; Chi-Chao Chan; Isa M Bernardini; Yuri V Sergeev; Monika B Dolinska; Ramakrishna P Alur; Murray H Brilliant; William A Gahl; Brian P Brooks
Journal:  J Clin Invest       Date:  2011-10       Impact factor: 14.808

Review 5.  From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.

Authors:  E A Lock; M K Ellis; P Gaskin; M Robinson; T R Auton; W M Provan; L L Smith; M P Prisbylla; L C Mutter; D L Lee
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

6.  Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.

Authors:  R M K Stewart; M C Briggs; J C Jarvis; J A Gallagher; L Ranganath
Journal:  JIMD Rep       Date:  2014-07-06

7.  Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Authors:  P Gissen; M A Preece; H A Willshaw; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Tyrosine administration decreases glutathione and stimulates lipid and protein oxidation in rat cerebral cortex.

Authors:  Angela M Sgaravatti; Alessandra S Magnusson; Amanda S de Oliveira; Andréa P Rosa; Caroline Paula Mescka; Fernanda R Zanin; Carolina D Pederzolli; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-08-18       Impact factor: 3.584

9.  Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1.

Authors:  Nathalie Guffon; Anders Bröijersén; Ingrid Palmgren; Mattias Rudebeck; Birgitta Olsson
Journal:  JIMD Rep       Date:  2017-06-23

10.  Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.

Authors:  L R Ranganath; A M Milan; A T Hughes; A S Davison; M Khedr; B P Norman; G Bou-Gharios; J A Gallagher; M Gornall; R Jackson; R Imrich; J Rovensky; M Rudebeck; B Olsson
Journal:  Mol Genet Metab Rep       Date:  2022-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.